AXQ Capital LP Takes $387,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

AXQ Capital LP purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,644 shares of the biopharmaceutical company's stock, valued at approximately $387,000.

A number of other institutional investors have also recently bought and sold shares of the business. Allworth Financial LP raised its position in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock valued at $140,000 after purchasing an additional 38 shares during the period. Nixon Peabody Trust Co. grew its stake in Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock valued at $540,000 after buying an additional 43 shares during the last quarter. IFP Advisors Inc raised its holdings in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 47 shares during the period. Nwam LLC lifted its position in Alnylam Pharmaceuticals by 5.8% during the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock worth $213,000 after acquiring an additional 50 shares during the last quarter. Finally, SYM FINANCIAL Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 6.2% during the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company's stock worth $260,000 after acquiring an additional 55 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Remove Ads

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares in the company, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock worth $19,958,097 over the last quarter. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY traded up $1.81 during trading hours on Thursday, hitting $271.02. The company's stock had a trading volume of 984,089 shares, compared to its average volume of 809,692. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a fifty day simple moving average of $258.98 and a 200-day simple moving average of $260.32. The company has a market capitalization of $35.09 billion, a P/E ratio of -124.89 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ALNY. Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Citigroup lifted their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Bank of America upped their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research report on Friday, March 21st. Finally, JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $280.00 to $328.00 in a report on Monday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $312.30.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.